In understanding the appropriate usage of Adbry (Tralokinumab-ldrm), it’s essential to comprehend the diverse dosage specifications catering to both adult and pediatric populations. This medication comes in various forms and strengths, each tailored to meet specific medical needs. Understanding the distinct dosages for special medical categories, such as those with particular health conditions or the elderly, is crucial for ensuring safe and effective administration.
Exploring the nuances of dosing for different age groups and medical categories is pivotal in providing comprehensive insights into the appropriate use of Adbry.
Adbry (Tralokinumab-ldrm) Adult Dosing
The recommended dosage for Adbry involves an initial dose of 600 mg, which equals four injections of 150 mg each, followed by a maintenance dosage of 300 mg, administered as two 150 mg injections every other week. After a 16-week treatment period, individuals with a body weight below 100 kg who attain clear or nearly clear skin may consider a reduced dosage of 300 mg every 4 weeks. Adbry is administered through subcutaneous injection.
| Dosing Stage | Dosage | Frequency |
| Initial Dosing | 600 mg (four 150 mg injections) | Every other week |
| Maintenance Dosing (Body Weight < 100 kg) | 300 mg (two 150 mg injections) | Every other week |
| Maintenance Dosing (Body Weight < 100 kg, clear or almost clear skin after 16 weeks) | 300 mg | Every 4 weeks |
| Administration Method | Subcutaneous injection | – |
Preparation for Use of Adbry (Tralokinumab-ldrm)
To prepare for injection, take Adbry prefilled syringes out of the refrigerator and allow them to reach room temperature (approximately 30 minutes for the 150 mg/mL prefilled syringes) without removing the needle cap.
Once removed from the refrigerator, these prefilled syringes can be stored at room temperature, up to 30°C (86°F), for a maximum of 14 days, after which they should be discarded.
Before administration, visually examine Adbry for any signs of particulate matter or discoloration. Adbry injection appears as a clear to opalescent, colorless to pale yellow solution. Refrain from using it if you notice visible particulate matter, discoloration, or cloudiness, as it should only be clear to opalescent, colorless to pale yellow. As Adbry lacks preservatives, any unused product should be disposed of appropriately.
Adbry (Tralokinumab-ldrm) Vital Administration
- The usage of Adbry should be supervised by a healthcare provider. Patients, once trained in the subcutaneous injection technique, may self-administer Adbry.
- It’s essential to provide patients and/or caregivers with proper training on preparation and administration as outlined in the “Instructions for Use”.
- For the initial 600 mg dose, each of the four Adbry 150 mg injections should be administered at distinct sites within the same body area.
- Subsequent 300 mg doses involve the administration of two ADBRY 150 mg injections at separate sites within the same body area.
- The subcutaneous injection is directed to the thigh or abdomen, avoiding the 2 inches (5 cm) around the navel.
- When administered by a caregiver, the upper arm is also a viable injection site.
- To ensure proper administration, rotate the body area for each subsequent set of injections. Avoid injecting Adbry into tender, damaged, bruised, or scarred skin.
